Literature DB >> 8730732

Effects of theophylline and rolipram on antigen-induced airway responses in neonatally immunized rabbits.

N Gozzard1, C M Herd, S M Blake, M Holbrook, B Hughes, G A Higgs, C P Page.   

Abstract

1. The effects of the xanthine, theophylline, a non-selective phosphodiesterase (PDE) inhibitor, and the phosphodiesterase type 4 (PDE 4) inhibitor, rolipram, were evaluated in a model of antigen-induced airway responses in the allergic rabbit. 2. Adult litter-matched NZW rabbits (2.5-3.9 kg), immunized within 24 h of birth with Alternaria tenuis antigen, were pretreated twice daily for 3 days with theophylline (3 mg kg-1, i.p) or rolipram (1 mg kg-1, i.p) prior to antigen challenge (Alternaria tenuis). For each drug-treated group, a parallel group of rabbits were pretreated with the appropriate vehicle. In all groups airway responsiveness to inhaled histamine and bronchoalveolar lavage (BAL) was performed 24 h before and after antigen-challenge. 3. Basal lung function in terms of resistance (RL, cmH2O 1(-1)s-1) and dynamic compliance (Cdyn, ml cmH2O-1) were unaltered by pretreatment with theophylline or rolipram compared to their respective vehicles 24 h prior to or post antigen challenge. 4. The acute bronchoconstriction induced by inhaled Alternaria tenuis aerosol was unaffected by pretreatment with theophylline or rolipram. 5. Airway hyperresponsiveness to inhaled histamine was indicated by reduced RL PC50 (2.4-3.5 fold) and Cdyn PC35 (2.5-2.6 fold) values 24 h after antigen challenge. Treatment with rolipram, but not theophylline, prevented the increase in responsiveness to inhaled histamine 24 h after antigen challenge. 6. Total cells per ml of BAL fluid increased 24 h after antigen challenge due to the recruitment of neutrophils and eosinophils. Antigen-induced increases in pulmonary neutrophils were unaffected; however, eosinophils were reduced 57.5% in theophylline and 82% in rolipram-treated rabbits. 7. Inhalation of Alternaria tenuis aerosol elicits an acute bronchoconstriction, followed 24 h later by an increased responsiveness to inhaled histamine and pulmonary neutrophil and eosinophil recruitment in the immunized rabbit. With the dosing regimes used, both rolipram and theophylline inhibited eosinophil recruitment, whilst only rolipram prevented the development of airway hyperresponsiveness. Neither agent inhibited the acute bronchoconstriction due to inhaled antigen.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8730732      PMCID: PMC1909441          DOI: 10.1111/j.1476-5381.1996.tb15299.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  37 in total

1.  A monoclonal antibody that detects a novel antigen on endothelial cells that is induced by tumor necrosis factor, IL-1, or lipopolysaccharide.

Authors:  S M Wellicome; M H Thornhill; C Pitzalis; D S Thomas; J S Lanchbury; G S Panayi; D O Haskard
Journal:  J Immunol       Date:  1990-04-01       Impact factor: 5.422

2.  Protective effect of antiasthma drugs on late asthmatic reactions and increased airway responsiveness induced by toluene diisocyanate in sensitized subjects.

Authors:  C Mapp; P Boschetto; L dal Vecchio; S Crescioli; N de Marzo; D Paleari; L M Fabbri
Journal:  Am Rev Respir Dis       Date:  1987-12

Review 3.  Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors.

Authors:  J A Beavo; D H Reifsnyder
Journal:  Trends Pharmacol Sci       Date:  1990-04       Impact factor: 14.819

4.  Our changing understanding of asthma.

Authors:  P J Barnes
Journal:  Respir Med       Date:  1989-05       Impact factor: 3.415

Review 5.  The inflammatory reaction in the airways in an animal model of the late asthmatic response.

Authors:  G L Larsen; M C Wilson; R A Clark; B L Behrens
Journal:  Fed Proc       Date:  1987-01

Review 6.  Pharmacologic management of reversible obstructive airways disease.

Authors:  M Weinberger; L Hendeles; R Ahrens
Journal:  Med Clin North Am       Date:  1981-05       Impact factor: 5.456

7.  The effect of theophylline and enprofylline on allergen-induced bronchoconstriction.

Authors:  R Pauwels; D Van Renterghem; M Van der Straeten; N Johannesson; C G Persson
Journal:  J Allergy Clin Immunol       Date:  1985-10       Impact factor: 10.793

8.  Airway cholinergic responsiveness in rabbits in relation to antigen sensitization and challenge.

Authors:  J W Bloom; C Baumgartener-Folkerts; J D Palmer; M Halonen
Journal:  Immunopharmacology       Date:  1988 May-Jun

Review 9.  The effects of theophylline on airway inflammation.

Authors:  R Pauwels
Journal:  Chest       Date:  1987-07       Impact factor: 9.410

10.  Theophylline does not inhibit allergen-induced increase in airway responsiveness to methacholine.

Authors:  D W Cockcroft; K Y Murdock; B P Gore; P M O'Byrne; P Manning
Journal:  J Allergy Clin Immunol       Date:  1989-05       Impact factor: 10.793

View more
  4 in total

1.  Low-level laser therapy (LLLT) acts as cAMP-elevating agent in acute respiratory distress syndrome.

Authors:  Flávia Mafra de Lima; Leonardo M Moreira; A B Villaverde; Regiane Albertini; Hugo C Castro-Faria-Neto; Flávio Aimbire
Journal:  Lasers Med Sci       Date:  2010-12-24       Impact factor: 3.161

Review 2.  Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?

Authors:  M A Giembycz
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

3.  Inhibition of bronchospasm and ozone-induced airway hyperresponsiveness in the guinea-pig by CDP840, a novel phosphodiesterase type 4 inhibitor.

Authors:  M Holbrook; N Gozzard; T James; G Higgs; B Hughes
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

4.  Effect of the glucocorticosteroid budesonide and a novel phosphodiesterase type 4 inhibitor CDP840 on antigen-induced airway responses in neonatally immunised rabbits.

Authors:  N Gozzard; A el-Hashim; C M Herd; S M Blake; M Holbrook; B Hughes; G A Higgs; C P Page
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.